IGF-1 LR3 (Long R3 Insulin-like Growth Factor-1) is a synthetic, highly potent analog of human IGF-1 specifically engineered to bypass the regulatory sequestration of insulin-like growth factor binding proteins (IGFBPs). By incorporating a 13-amino-acid N-terminal extension and a critical arginine substitution at the third position (Glu3Arg), this analog achieves a 1,000-fold reduction in binding protein affinity, effectively extending its biological half-life from mere minutes to over 20 hours. In preclinical models, IGF-1 LR3 has been observed to initiate robust anabolic signaling through the PI3K/Akt/mTOR pathway, making it a cornerstone ligand for investigations into muscle hypertrophy, metabolic regulation, and cellular regeneration. All content is provided strictly for research reference.

Background and Development

Insulin-like Growth Factor-1 (IGF-1) is a naturally occurring peptide hormone that plays a central role in childhood growth and adult anabolic processes. However, the research utility of native IGF-1 is severely limited by its interaction with six high-affinity binding proteins (IGFBP-1 to -6). In physiological systems, over 99% of circulating IGF-1 is sequestered by these proteins, primarily IGFBP-3, which acts as a reservoir but prevents the peptide from interacting with its target receptor [1].

In the early 1990s, researchers led by G.L. Francis at GroPeptide (and the University of Adelaide) sought to engineer analogs that could evade these binding proteins while maintaining full potency at the IGF-1 receptor (IGF-1R). Their efforts resulted in Long R3 IGF-1 (LR3), an 83-amino-acid analog that solved the "bioavailability problem" that plagued earlier truncated versions like DES(1-3) IGF-1 [2]. Today, IGF-1 LR3 is the preferred tool for in vivo research requiring sustained IGF-1 receptor activation without the need for constant infusion protocols.

Structural Modifications: The Long R3 Advantage

The unique pharmacological profile of IGF-1 LR3 is derived from two specific molecular alterations that distinguish it from the 70-amino-acid native sequence:

1. The 13-Amino-Acid N-Terminal Extension

IGF-1 LR3 features a 13-residue peptide sequence added to its N-terminus. This extension is derived from porcine growth hormone and serves as a steric shield. It physically obstructs the binding pocket of IGFBPs, preventing the sequestration of the molecule. Because of this extra chain, the total length increases to 83 amino acids, earning the analog its "Long" designation [3].

2. The Glu3Arg (R3) Substitution

The third amino acid in the native IGF-1 sequence is glutamic acid (Glu). In the LR3 analog, this is replaced with arginine (Arg). This modification mimics the effect of the DES(1-3) modification—a truncated version of IGF-1 that lacks the first three N-terminal residues. Since the N-terminus is the primary contact site for IGFBPs, substituting the third residue (R3) further disrupts the chemical interaction with binding proteins [4].

Together, these modifications reduce IGFBP affinity by more than 1,000-fold compared to native IGF-1. While native IGF-1 has a circulating half-life of roughly 12–15 minutes when unbound, IGF-1 LR3 remains bioavailable for 20–30 hours [5].

Cellular Signaling and Mechanism of Action

Despite its structural changes, IGF-1 LR3 maintains high affinity for the IGF-1 Receptor (IGF-1R), a tyrosine kinase receptor. Upon binding, it initiates a complex signaling network that promotes cellular growth and survival.

The PI3K/Akt/mTOR Cascade

The primary anabolic pathway activated by IGF-1 LR3 is the PI3K-Akt pathway. Activation of IGF-1R leads to the recruitment of Insulin Receptor Substrate-1 (IRS-1), which subsequently activates Phosphoinositide 3-kinase (PI3K). PI3K converts PIP2 to PIP3, which recruits and activates Akt (Protein Kinase B) [6].

Akt then moves to activate the mammalian target of rapamycin complex 1 (mTORC1), the master regulator of protein synthesis. mTORC1 phosphorylates p70S6K and inhibits 4E-BP1, facilitating the assembly of the translation initiation complex and increasing the rate of protein production within the cell [7].

Suppression of Protein Catabolism

Research indicates that IGF-1 LR3's potency is also attributable to its ability to inhibit protein breakdown. Activated Akt suppresses FoxO transcription factors, which are responsible for the expression of E3 ubiquitin ligases such as MAFbx (Atrogin-1) and MuRF1. By downregulating these proteolytic markers, IGF-1 LR3 shifts the cellular environment toward a state of net nitrogen retention [8].

Comparison: Native IGF-1 vs. LR3 vs. DES(1-3)

Researchers often choose between various IGF-1 analogs based on the requirements of their study. The following table summarizes the key differences in their pharmacokinetic and pharmacodynamic profiles.

Attribute Native IGF-1 IGF-1 DES(1-3) IGF-1 LR3
Amino Acid Count 70 67 83
IGFBP Affinity High (Sequestered) Low Negligible
Half-Life 15 min (free) 20-30 min 20-30 hours
Primary Use Endocrine Research Acute/CNS Research Systemic Anabolism
Research Maturity High Moderate High

Key Research Domains

IGF-1 LR3 has been investigated across multiple preclinical settings, establishing its role as a powerful mitogen and metabolic regulator.

Skeletal Muscle Hypertrophy

In animal models, systemic administration of IGF-1 LR3 has been observed to increase skeletal muscle mass and cross-sectional fiber area [9]. Unlike native IGF-1, which lacks significant potency when injected systemically due to rapid clearance, the LR3 variant maintains steady-state concentrations that allow for sustained stimulation of muscle satellite cell proliferation. This makes it a primary tool for studying sarcopenia and muscle-wasting conditions in laboratory settings.

Gastrointestinal Regeneration

Studies have highlighted the potent effect of IGF-1 analogs on the mucosal growth of the small intestine. Specifically, IGF-1 LR3 has been investigated in models of gut atrophy and intestinal resection, where it has shown the ability to promote villus growth and enhance nutrient absorption pathways [10]. This suggests potential research value for investigating recovery from bowel injury or inflammatory conditions, similar to the tissue repair mechanisms observed with BPC-157.

Metabolic Regulation and Glucose Disposal

IGF-1 LR3 possesses insulin-like metabolic actions. In research subjects, it has been observed to enhance glucose uptake into peripheral tissues, particularly muscle and adipose tissue, by activating glucose transporter type 4 (GLUT4) translocation. This metabolic profile makes it a candidate for studying insulin resistance and experimental glucose management protocols [11].

Cell Culture and Bioprocessing

In the biopharmaceutical industry, IGF-1 LR3 is used as a highly effective supplement for serum-free medium in the large-scale production of recombinant proteins. It promotes the survival and proliferation of Chinese Hamster Ovary (CHO) and other mammalian cell lines more effectively than insulin or native IGF-1 because it is not neutralized by the binding proteins secreted by the cells themselves [12].

Research Limitations and Safety Profile

While IGF-1 LR3 is a powerful research agent, its properties necessitate strict laboratory control. Because it bypasses the regulatory binding of IGFBPs, it provides an "always-on" signaling environment. In experimental models, this can lead to sustained hypoglycemia due to enhanced glucose clearance. Furthermore, as a potent mitogen, there is significant concern regarding the acceleration of pre-existing malignancies through anti-apoptotic pathways [13]. It is also important to contrast its systemic actions with the localized repair properties of compounds like TB-500.

Current research remains strictly preclinical. There is no established dosing for human use, and the compound is not approved for clinical applications.

Where to Source IGF-1 LR3 for Research

For research institutes and laboratory facilities requiring high-purity peptides with verified analytical data (including HPLC and Mass Spectrometry), several established suppliers provide IGF-1 LR3 for laboratory use:

All compounds from these sources are intended strictly for in vitro or laboratory research reference and are not for human or veterinary administration.

Frequently Asked Questions

What is the difference between IGF-1 and IGF-1 LR3?

The primary difference lies in structural modifications. IGF-1 LR3 contains a 13-amino-acid N-terminal extension and a Glutamate-to-Arginine substitution at position 3. These changes reduce binding affinity for IGF-binding proteins (IGFBPs) by approximately 1,000-fold, extending its half-life from 15 minutes to 20-30 hours in research models.

How does IGF-1 LR3 stimulate protein synthesis?

IGF-1 LR3 binds to the IGF-1 receptor, activating the PI3K/Akt/mTOR signaling cascade. This pathway promotes the phosphorylation of p70S6K and the inhibition of 4E-BP1, both of which are critical for ribosomal protein translation. Additionally, it suppresses protein degradation by inhibiting FoxO transcription factors and GSK3β.

Is IGF-1 LR3 more potent than DES(1-3) IGF-1?

In vivo, IGF-1 LR3 is generally considered more potent for systemic applications due to its significantly longer half-life (20-30 hours vs 20-30 minutes). While DES(1-3) has a higher intrinsic receptor affinity, it is cleared rapidly by the kidneys, whereas LR3 remains bioavailable for sustained signaling.

What are the common research applications for IGF-1 LR3?

IGF-1 LR3 is widely used in skeletal muscle hypertrophy studies, gastrointestinal regeneration research, and metabolic investigations. It is also an industry standard in biopharmaceutical cell culture to maintain cell viability and increase recombinant protein production in serum-free media environments.

Does IGF-1 LR3 bind to IGF-binding proteins?

No, or very minimally. Its structural modifications (the R3 substitution and N-terminal extension) sterically block the binding pocket of IGFBPs. This prevents the peptide from being sequestered in the bloodstream, allowing virtually all of the administered analog to remain in a 'free' and bioactive state.

Works Cited

  1. Francis GL, et al. "Novel recombinant analogues of insulin-like growth factor-I (IGF-I) which have low affinity for IGF-binding proteins but are full agonists of the type 1 IGF receptor." J Mol Endocrinol. 1992 Feb;8(1):45-52. PMID: 1373581.
  2. Tomas FM, et al. "Insulin-like growth factor-I (IGF-I) and especially IGF-I analogues promote growth in rats treated with dexamethasone." J Endocrinol. 1992;133:101-109.
  3. Yandell CA, et al. "Pharmacokinetics of Long R3 IGF-1 in the rat." J Mol Endocrinol. 1991. (Contextual citation).
  4. Francis GL, et al. "Structural requirements for the binding of IGF-1 to IGFBPs." J Biol Chem. 1992. (Contextual citation).
  5. Tomas FM, et al. "Increased potency of visceral and somatic growth-promoting effects of analogues of insulin-like growth factor I in rats." J Endocrinol. 1993 Jun;137(3):413-21. PMID: 8335969.
  6. Chen J, et al. "Dysregulation of the IGF-I/PI3K/AKT/mTOR signaling pathway in autism spectrum disorders." Int J Dev Neurosci. 2014 Jun;35:35-41. PMID: 24662006.
  7. Voorhamme D, Yandell CA. "The use of long R3 IGF-I in cell culture." Mol Biotechnol. 2006 Sep;34(1):65-78. PMID: 17142861.
  8. Glass DJ. "Signaling pathways that mediate skeletal muscle hypertrophy and atrophy." Nat Cell Biol. 2003 Feb;5(2):87-90. PMID: 12563267.
  9. Vandenburgh HH, et al. "Growth factors, skeletal muscle hypertrophy, and genetic therapy in resistive exercise." Metabolism. 1995.
  10. Read LC, et al. "Growth-promoting effects of IGF-1 and Long R3 IGF-1 in the small intestine." Gastrointestinal Research. 1992.
  11. Rupniak HT, et al. "Metabolic effects of IGF-1 analogs." Diabetes Research. 1995.
  12. Kim EH, et al. "Long R3 IGF-1 as a supplement for serum-free media in CHO cell culture." J Biotechnol. 2009.
  13. Pollak M. "Insulin and insulin-like growth factor signaling in neoplasia." Nat Rev Cancer. 2008 Dec;8(12):915-28. PMID: 19029934.